Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
Slide 59
Strengthened insulin volume market share in Region Latin
America
tMU
15
12
9
6
3
Latin America insulin market by segment
Latin America modern and new-generation
insulin volume shares
Device penetration
Modern insulin penetration
CAGR volume¹: 12.4%
Penetration
CAGR value¹: 10.7%
60%
70%
Fast-acting
60%
Premix
50%
40%
40%
30%
Long-acting
20%
20%
10%
0%
0%
Nov
2017
Nov
2012
-
Novo Nordisk
Eli Lilly
Sanofi
42%
31%
15%
Nov
2012
1 CAGR for 5-year period.
Note: IMS only covers the following 4 markets in Latin America (retail data): Argentina, Brazil, Colombia, Mexico
Source: IQVIA (formerly IMS) monthly MAT data Nov, 2017 volume and value (DKK) figures
MI: Modern insulin; NGI: New-generation insulin
Note: Only top-3 shown
Nov
2017
Source: IQVIA (formerly IMS) monthly MAT data Nov, 2017 volume figures, numbers do not add up to
100% due to smaller insulin manufacturers not included
MI: Modern insulin; NGI: New-generation insulin
changing
diabetes®
novo nordiskView entire presentation